LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,203
تعداد مقالات10,960
تعداد مشاهده مقاله74,025,783
تعداد دریافت فایل اصل مقاله43,758,331
Momeni, Niusha, Nili, Fatemeh, Ameli, Fereshteh, Sarmadi, Soheila, Mirzaian, Elham, Moravej-Salehi, Farnaz, Zamani, Narges. (1404). Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma. سامانه مدیریت نشریات علمی, 16(3), 238-248. doi: 10.30476/mejc.2024.102620.2099
Niusha Momeni; Fatemeh Nili; Fereshteh Ameli; Soheila Sarmadi; Elham Mirzaian; Farnaz Moravej-Salehi; Narges Zamani. "Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma". سامانه مدیریت نشریات علمی, 16, 3, 1404, 238-248. doi: 10.30476/mejc.2024.102620.2099
Momeni, Niusha, Nili, Fatemeh, Ameli, Fereshteh, Sarmadi, Soheila, Mirzaian, Elham, Moravej-Salehi, Farnaz, Zamani, Narges. (1404). 'Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma', سامانه مدیریت نشریات علمی, 16(3), pp. 238-248. doi: 10.30476/mejc.2024.102620.2099
Momeni, Niusha, Nili, Fatemeh, Ameli, Fereshteh, Sarmadi, Soheila, Mirzaian, Elham, Moravej-Salehi, Farnaz, Zamani, Narges. Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma. سامانه مدیریت نشریات علمی, 1404; 16(3): 238-248. doi: 10.30476/mejc.2024.102620.2099

Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma

Middle East Journal of Cancer
مقاله 4، دوره 16، شماره 3، مهر 2025، صفحه 238-248    اصل مقاله (3.14 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2024.102620.2099
نویسندگان
Niusha Momeni1؛ Fatemeh Nili* 1؛ Fereshteh Ameli1؛ Soheila Sarmadi2؛ Elham Mirzaian3؛ Farnaz Moravej-Salehi2؛ Narges Zamani4
1Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Department of Pathology, Yas Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3Department of Pathology, Dr Shariati Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Department of Gynecology Oncology, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Background: Endocervical adenocarcinoma (ENCA) has poor prognosis and is increasing in developing countries. Human epidermal growth factor receptor 2 (HER2) overexpression in ENCA is not fully known. The aim of this study was to assess the prevalence and clinicopathological features of HER2 overexpression in ENCA.
Method: In this cohort study, 48 ENCA cases were reclassified using the World Health Organization (WHO) classification. Whole-tissue sections were stained for HER2 by immunohistochemistry (IHC) and scored using 2017 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) protocol (negative= 0, 1+, equivocal= 2+, and positive= 3+). Fluorescent in situ hybridization (FISH) assay was performed for 2+ stained cases. Invasion growth pattern and clinicopathologic features were investigated. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) and Statistical software for data science (STATA) with chi square, Fischer exact, independent sample t-test, and one-way Analysis of Variance (ANOVA) at 0.05 significance level.
Results: 16.6% of ENCAs overexpressed HER2, IHC3+ (n=6) and IHC2+ (n=2). No human papilloma virus (HPV)-independent case was found. HER2 was expressed in half of the invasive stratified mucin-producing carcinomas (ISMICs) (P < 0.05) and was not associated with stage, metastasis, lymph-vascular space invasion, lymph node metastasis, or pattern of invasion (P > 0.05). 
Conclusion: ENCAs, including HPV-associated subtypes, overexpress HER2 in about 16.6% of the cases. Overexpression in ISMIC is significantly higher than the other subtypes, which can be considered for therapeutic trials in this histopathologic subcategory.

تازه های تحقیق

Niusha Momeni (PubMed)

Fatemeh Nili (Google Scholar)

کلیدواژه‌ها
Uterine cervical neoplasms؛ HER2 protein؛ Immunohistochemistry؛ Prognosis
مراجع
  1. Bosse T, Lax S, Abu-Rustum N, Matias-Guiu X. The Role of predictive biomarkers in endocervical adenocarcinoma: Recommendations from the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2021;40(Suppl 1):S102-S110. doi: 10.1097/PGP.0000000000000755. PMID: 33570867; PMCID: PMC7969151.
  2. He WQ, Li C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol Oncol. 2021;163(3):583-92. doi: 10.1016/j.ygyno.2021.10.075. PMID: 34688503.
  3. Huang J, Deng Y, Boakye D, Tin MS, Lok V, Zhang L, et al. Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis. Gynecol Oncol. 2022;164(1):85-92. doi: 10.1016/j.ygyno.2021.11.005. PMID: 34799136.
  4. Stolnicu S, Park KJ, Kiyokawa T, Oliva E, McCluggage WG, Soslow RA. Tumor typing of ENCA: Contemporary review and recommendations from the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2021;40(Suppl 1):S75-S91. doi: 10.1097/PGP.0000000000000751. PMID: 33570865; PMCID: PMC7888380.
  5. Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021;81(10):1145-53. doi: 10.1055/a-1545-4279. PMID: 34629493; PMCID: PMC8494521.
  6. Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Research. 2022;13:200238. doi: 10.1016/j.tvr.2022.200238. PMID: 35460940.
  7. Moreno-Acosta P, Vallard A, Carrillo S, Gamboa O, Romero-Rojas A, Molano M, et al. Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma. Radiat Oncol. 2017;12(1):1-9. doi: 10.1186/s13014-017-0856-2. PMID: 28716107.
  8. Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K, et al. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol. 2017;28(2):e19. doi: 10.3802/jgo.2017.28.e19. PMID: 28028992; PMCID: PMC5323286.
  9. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189-94. doi: 10.1038/nature25475. PMID: 29420467.
  10. Cousin S, Khafia E, Crombe A, Laizet Y, Lucchesi C, Toulmonde M, et al. Targeting ERBB2 mutations in solid tumors: biological and clinical implications. J Hematol Oncol. 2018 ;11(1):86. doi: 10.1186/s13045-018-0630-4. PMID: 29941010.
  11. Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, et al. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proc Natl Acad Sci. 2019;116(45):22730-6. doi: 10.1073/pnas.1911385116. PMID: 31624127.
  12. Vakiani E. HER2 testing in gastric and gastroesophageal adenocarcinomas. Adv Anat Pathol. 2015;22(3):194-201. doi: 10.1097/PAP.0000000000000067. PMID: 25844677.
  13. Wolff AC, Hammond ME, Allison KH, Harvey BE, Mangu PB, Bartlett JM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364-82. doi: 10.5858/arpa.2018-0902-SA. PMID: 29846104.
  14. Ueda A, Takasawa A, Akimoto T, Takasawa K, Aoyama T, et al. Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix. PLoS One. 2017;12(8):e0184123. doi: 10.1371/journal.pone.0184123. PMID: 28859123.
  15. Kunos CA, Fabian D, Piecoro DW, Napier D, Miller RW, Ueland FR. Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky. Front Oncol. 2023;13:948348. doi: 10.3389/fonc.2023.948348. PMID: 36761943.
  16. Li J, Xue X, Zhang Y, Ding F, Wu W, Liu C, et al. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer. Gynecol Oncol. 2023;175:133-41. doi: 10.1016/j.ygyno.2023.05.071. PMID: 37356314.
  17. Salarzaei M, van de Laar RLO, Ewing-Graham PC, Najjary S, van Esch E, van Beekhuizen HJ, et al. Unraveling differences in molecular mechanisms and immunological contrasts between squamous cell carcinoma and adenocarcinoma of the cervix. Int J Mol Sci. 2024;25(11):6205. doi: 10.3390/ijms25116205. PMID: 38892393.
  18. Mentrikoski MJ, Stoler MH. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas. Am J Surg Pathol. 2014;38(6):844-51. doi: 10.1097/PAS.0000000000000182. PMID: 24698965.
  19. Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y. Anti-HER2 cancer-specific mAb, H2Mab-250-hG1, possesses higher complement-dependent cytotoxicity than trastuzumab. Int J Mol Sci. 2024;25(15):8386. doi: 10.3390/ijms25158386. PMID: 39125956.
  20. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40(6):770-80. doi: 10.1016/j.ctrv.2014.02.008. PMID: 24656976.
  21. Wang S, Zhou X, Niu S, Chen L, Zhang H, Chen H, et al. Assessment of HER2 in gastric-type ENCA and its prognostic significance. Mod Pathol. 2023;36(6):100148. doi: 10.1016/j.modpat.2023.100148. PMID: 36841435.
  22. Shi H, Shao Y, Lu W, Lu B. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International ENCA Criteria and Classification. J Pathol Clin Res. 2021;7(1):86-95. doi: 10.1002/cjp2.184. PMID: 33089969.
  23. Itkin B, Garcia A, Straminsky S, Adelchanow ED, Pereyra M, Haab GA, et al. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis. PLoS One. 2021;16(9):e0257976. doi: 10.1371/journal.pone.0257976. PMID: 34591928.
  24. Nakamura A, Yamaguchi K, Minamiguchi S, Murakami R, Abiko K, Hamanishi J, et al. Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Med Mol Morphol. 2019;52(1):52-9. doi: 10.1007/s00795-018-0202-2. PMID: 29992451.
  25. Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, et al. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. Am J Obstet Gynecol. 2017;217(4):432.e1-432.e17. doi: 10.1016/j.ajog.2017.05.068. PMID: 28599900.
  26. Abada E, Kim S, Jang H, Kheil M, Singh K, Bandyopadhyay S, et al. Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions. Gynecol Oncol. 2024;185:25-32. doi: 10.1016/j.ygyno.2024.01.048. PMID: 38364692.
  27. Park E, Kim YT, Kim S, Nam EJ, Cho NH. Immunohistochemical and genetic characteristics of HPV-associated endocervical carcinoma with an invasive stratified mucin-producing carcinoma (ISMC) component. Mod Pathol. 2021;34(9):1738-49. doi: 10.1038/s41379-021-00829-3. PMID: 34103667.
آمار
تعداد مشاهده مقاله: 321
تعداد دریافت فایل اصل مقاله: 109


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب